The basis for drug treatment of the overactive bladder

被引:0
|
作者
K. E. Andersson
C. Chapple
A. Wein
机构
[1] Department of Clinical Pharmacology,
[2] Lund University Hospital,undefined
[3] S-221 85 Lund,undefined
[4] Sweden e-mail: Karl-Erik.Andersson@klinfarm.lu.se Tel.: +46-46-173350; Fax: +46-46-2111987,undefined
[5] Department of Urology,undefined
[6] Royal Hallamshire Hospital,undefined
[7] Sheffield,undefined
[8] UK,undefined
[9] Division of Urology,undefined
[10] University of Pennsylvania Health System,undefined
[11] Philadelphia,undefined
[12] USA,undefined
来源
World Journal of Urology | 2001年 / 19卷
关键词
Key words urinary incontinence; bladder contraction; micturition reflex; neurotransmitters; muscarinic receptors; sensory mechanisms;
D O I
暂无
中图分类号
学科分类号
摘要
 The normal bladder functions, storage and elimination of urine, are dependent on neural circuits in the brain and spinal cord that coordinate the activity of the detrusor and that of the smooth and striated muscles of the outflow region. Disturbances at different levels may cause the overactive bladder (OAB) syndrome, characterized by urge, frequency and urge incontinence. Knowledge about the mechanisms controlling both normal and abnormal micturition is mandatory for the detection of targets for pharmacological intervention. Such targets may be found in the central nervous system (CNS) or peripherally. Several CNS transmitters can modulate voiding, but few drugs with a defined CNS site of action have been demonstrated to be clinically useful. Traditionally, drugs for treatment of OAB have had a peripheral site of action. Antimuscarinics are still the gold standard, but their wellknown side effects have focused interest on other modalities of treatment. Promising preclinical results have been obtained for some principles, but so far there are few positive clinical proof of concept studies available.
引用
收藏
页码:294 / 298
页数:4
相关论文
共 50 条
  • [1] The basis for drug treatment of the overactive bladder
    Andersson, KE
    Chapple, C
    Wein, A
    WORLD JOURNAL OF UROLOGY, 2001, 19 (05) : 294 - 298
  • [2] The overactive bladder: Pharmacologic basis of drug treatment
    Andersson, KE
    UROLOGY, 1997, 50 (6A) : 74 - 84
  • [3] Treatment of overactive bladder: Other drug mechanisms
    Andersson, KE
    UROLOGY, 2000, 55 (5A) : 51 - 57
  • [4] Drug persistence and adherence in the treatment of overactive bladder
    Radomski, Sidney B.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (9-10): : 351 - 352
  • [5] Behavioral Versus Drug Treatment for Overactive Bladder in Men: The Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial
    Burgio, Kathryn L.
    Goode, Patricia S.
    Johnson, Theodore M., II
    Hammontree, Lee
    Ouslander, Joseph G.
    Markland, Alayne D.
    Colli, Janet
    Vaughan, Camille P.
    Redden, David T.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2011, 59 (12) : 2209 - 2216
  • [6] A myogenic basis for the overactive bladder
    Brading, AF
    UROLOGY, 1997, 50 (6A) : 57 - 67
  • [7] A neurologic basis for the overactive bladder
    de Groat, WC
    UROLOGY, 1997, 50 (6A) : 36 - 52
  • [8] How to choose the initial drug treatment for overactive bladder
    MacDiarmid S.A.
    Current Urology Reports, 2007, 8 (5) : 364 - 369
  • [9] How to choose the initial drug treatment for overactive bladder
    MacDiarmid S.A.
    Current Bladder Dysfunction Reports, 2008, 3 (1) : 41 - 46
  • [10] Drug therapy for an overactive bladder
    Thiagamoorthy, Ganesh
    Cardozo, Linda
    Srikrishna, Sushma
    WOMENS HEALTH, 2015, 11 (04) : 445 - 448